Mirodenafil (BioDeep_00000180974)

   

human metabolite blood metabolite


代谢物信息卡片


5-Ethyl-2-(5-(4-(2-hydroxyethyl)piperazine-1-sulfonyl)-2-propoxyphenyl)-7-propyl-3,5-dihydro-4H-pyrrolo(3,2-D)pyrimidin-4-one

化学式: C26H37N5O5S (531.2515272)
中文名称: 米罗那非
谱图信息: 最多检出来源 Homo sapiens(blood) 87.5%

分子结构信息

SMILES: CCCC1=CN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CCO)OCCC)CC
InChI: InChI=1S/C26H37N5O5S/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33)

描述信息

D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors > D058986 - Phosphodiesterase 5 Inhibitors
C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor > C2127 - cGMP Phosphodiesterase Inhibitor

同义名列表

4 个代谢物同义名

5-Ethyl-2-(5-(4-(2-hydroxyethyl)piperazine-1-sulfonyl)-2-propoxyphenyl)-7-propyl-3,5-dihydro-4H-pyrrolo(3,2-D)pyrimidin-4-one; 5-ethyl-2-(5-{[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl}-2-propoxyphenyl)-7-propyl-3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one; 5-Ethyl-2-(5-{[4-(2-hydroxyethyl)piperazin-1-yl]sulphonyl}-2-propoxyphenyl)-7-propyl-5H-pyrrolo[3,2-D]pyrimidin-4-ol; MIRODENAFIL



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Ji Sung Shim, Jae Hyun Bae. Drug Concentration in Rat Plasma, Bladder, and Prostate After Mirodenafil Administration in a Chronic Pelvic Ischemia Model. Urology. 2016 May; 91(?):244.e1-5. doi: 10.1016/j.urology.2016.02.017. [PMID: 26919966]
  • Doo-Yeoun Cho, Soo Hyeon Bae, Ji-Hong Shon, Soo Kyung Bae. High-sensitive LC-MS/MS method for the simultaneous determination of mirodenafil and its major metabolite, SK-3541, in human plasma: application to microdose clinical trials of mirodenafil. Journal of separation science. 2013 Mar; 36(5):840-8. doi: 10.1002/jssc.201200919. [PMID: 23390072]
  • Yook-Hwan Noh, Hyeong-Seok Lim, Sang-Heon Cho, Jong-Lyul Ghim, Sangmin Choe, Jin Ah Jung, Mi Jo Kim, Yo Han Kim, Seok-Joon Jin, Soon Bae Kim, Jung Sik Park, Sang Koo Lee, Won Seok Yang, Jai Won Chang, Bongyong Lee, Kyun-Seop Bae. Assessment of the influence of severe renal impairment on the pharmacokinetics of mirodenafil in Korean male volunteers. International journal of clinical pharmacology and therapeutics. 2012 Dec; 50(12):880-8. doi: 10.5414/cp201721. [PMID: 23006442]
  • T K Kim, H H Yoo, J H Park. Validated LC-MS/MS method for the determination of mirodenafil in rat plasma and its application to a comparative pharmacokinetic study of the free base and hydrochloride salt forms of mirodenafil. Arzneimittel-Forschung. 2012 Jul; 62(7):351-4. doi: 10.1055/s-0032-1312665. [PMID: 22692776]
  • J Y Lee, S Y Cho, C Y Oh, U S Ha, S H Lee, S Y Park, H S Moon, S W Lee. Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. International journal of impotence research. 2011 Nov; 23(6):249-56. doi: 10.1038/ijir.2011.34. [PMID: 21814227]
  • Jung Jun Kim, Deok Hyun Han, Soo Hyun Lim, Tae Hun Kim, Mee Ree Chae, Kyung Jin Chung, Sung Chul Kam, Ju-Hong Jeon, Jong Kwan Park, Sung Won Lee. Effects of Ginkgo biloba extracts with mirodenafil on the relaxation of corpus cavernosal smooth muscle and the potassium channel activity of corporal smooth muscle cells. Asian journal of andrology. 2011 Sep; 13(5):742-6. doi: 10.1038/aja.2010.184. [PMID: 21478894]
  • Rosario Leonardi, Matteo Alemanni. The management of erectile dysfunction: innovations and future perspectives. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica. 2011 Mar; 83(1):60-2. doi: NULL. [PMID: 21585174]
  • Kwang-Hee Shin, Bo-Hyung Kim, Tae-Eun Kim, Jae Woo Kim, Sojeong Yi, Seo-Hyun Yoon, Joo-Youn Cho, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. Clinical therapeutics. 2009 Dec; 31(12):3009-20. doi: 10.1016/j.clinthera.2009.12.012. [PMID: 20110038]
  • Young H Choi, Young S Lee, Tae K Kim, Bong-Y Lee, Myung G Lee. Faster clearance of mirodenafil in rats with acute renal failure induced by uranyl nitrate: contribution of increased protein expression of hepatic CYP3A1 and intestinal CYP1A1 and 3A1/2. The Journal of pharmacy and pharmacology. 2009 Oct; 61(10):1325-32. doi: 10.1211/jpp/61.10.0008. [PMID: 19814864]
  • Young H Choi, Young S Lee, Soo H Bae, Tae K Kim, Bong-Y Lee, Myung G Lee. Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats. Biopharmaceutics & drug disposition. 2009 Sep; 30(6):305-17. doi: 10.1002/bdd.669. [PMID: 19639551]
  • Sang Kyu Lee, Yoon Kim, Tae Kon Kim, Guang-Jin Im, Bong-Yong Lee, Dong-Hyun Kim, Changbae Jin, Hye Hyun Yoo. Determination of mirodenafil and sildenafil in the plasma and corpus cavernous of SD male rats. Journal of pharmaceutical and biomedical analysis. 2009 Feb; 49(2):513-8. doi: 10.1016/j.jpba.2008.11.004. [PMID: 19095395]
  • H S Lee, E J Park, H Y Ji, S Y Kim, G-J Im, S M Lee, I J Jang. Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil. Xenobiotica; the fate of foreign compounds in biological systems. 2008 Jan; 38(1):21-33. doi: 10.1080/00498250701708521. [PMID: 18098061]
  • Beom Soo Shin, Seul Ki Hu, John Kim, Joon Gyo Oh, Won-No Youn, Bongyong Lee, Key An Um, Dae-Kee Kim, Ju Young Lee, Sun Dong Yoo. Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study. Journal of pharmaceutical and biomedical analysis. 2007 Sep; 45(1):176-184. doi: 10.1016/j.jpba.2007.06.021. [PMID: 17689219]
  • Hye-hyun Yoo, Nam-sun Kim, Guang-jin Im, Dong-hyun Kim. Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats. Acta pharmacologica Sinica. 2007 Aug; 28(8):1247-53. doi: 10.1111/j.1745-7254.2007.00611.x. [PMID: 17640490]
  • Jaeick Lee, Hye Hyun Yoo, Kwang Jin Rhim, Dong-Ryul Sohn, Dong-Hyun Kim. Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats. Rapid communications in mass spectrometry : RCM. 2007; 21(7):1139-49. doi: 10.1002/rcm.2943. [PMID: 17318927]